ReviewJournal of gastroenterology2020
Manipulating resident microbiota to enhance regulatory immune function to treat inflammatory bowel diseases.
Review in Journal of gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 2 syntheses or guidelines pooled it, 84 citations in OpenAlex.
- Preclinical relevance of probiotics in type 2 diabetes: A systematic review.International journal of experimental pathology · 2020Pooled it
- Ocular Microbiota and Intraocular Inflammation.Frontiers in immunology · 2020Pooled it
- Defined human Clostridia consortia reverse colitis via dual effects of tryptophan metabolites on microbiota and immunity.Cell host & microbe · 2026Article
- Angiogenesis in Inflammatory Bowel Disease.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Research of heat-killed Loigolactobacillus coryniformis NA-3 and Lactiplantibacillus plantarum NA as potential substitutes for live strains in immune regulation and anti-inflammatory effects.World journal of microbiology & biotechnology · 2026Article
- Engineering bacteriophages for gut health: precision antimicrobials and beyond.Journal of nanobiotechnology · 2026Review
- Dietary eggshell membrane modulates gut microbiota and alleviates AOM/DSS-induced colonic inflammation in mice.Bioscience reports · 2026Article
- Adverse drug reaction assessment of pembrolizumab and nivolumab in esophageal cancer treatment based on the US FAERS database.Frontiers in immunology · 2026Article
- Gut Permeability and Microbiota in Parkinson's Disease: Mechanistic Insights and Experimental Therapeutic Strategies.International journal of molecular sciences · 2025Review
- Early subclinical stages of the inflammatory bowel diseases: insights from human and animal studies.American journal of physiology. Gastrointestinal and liver physiology · 2025Review
- Persistent Activation of the P2X7 Receptor Underlies Chronic Inflammation and Carcinogenic Changes in the Intestine.International journal of molecular sciences · 2024Review
- Exploring the causal relationship between Takayasu arteritis and inflammatory bowel disease using Mendelian randomization.Immunologic research · 2024Article
- Wake up and smell the coffee: The potential of faecal volatile organic compounds in paediatric inflammatory bowel disease.United European gastroenterology journal · 2024Article
- The Role of the Gut Microbiome in Inflammatory Bowel Disease: The Middle East Perspective.Journal of personalized medicine · 2024Article
- Combination therapy with probiotics and anti-PD-L1 antibody synergistically ameliorates sepsis in mouse model.Heliyon · 2024Article
- The gut microbiome in systemic lupus erythematosus: lessons from rheumatic fever.Nature reviews. Rheumatology · 2024Review
- Mechanisms and Clinical Implications of Human Gut Microbiota-Drug Interactions in the Precision Medicine Era.Biomedicines · 2024Review
- The microbiome landscape in pediatric Crohn's disease and therapeutic implications.Gut microbes · 2023Review
- Relationship among Chinese herb polysaccharide (CHP), gut microbiota, and chronic diarrhea and impact of CHP on chronic diarrhea.Food science & nutrition · 2023Review
- D-Lactate: Implications for Gastrointestinal Diseases.Children (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Altered intestinal microbial composition (dysbiosis) and metabolic products activate aggressive mucosal immune responses that mediate inflammatory bowel diseases (IBD). This dysbiosis impairs the function of regulatory immune cells, which normally promote mucosal homeostasis. Normalizing and maintaining regulatory immune cell function by correcting dysbiosis provides a promising approach to treat IBD patients. However, existing microbe-targeted therapies, including antibiotics, prebiotics, probiotics, and fecal microbial transplantation, provide variable outcomes that are not optimal for current clinical application. This review discusses recent progress in understanding the dysbiosis of IBD and the basis for therapeutic restoration of homeostatic immune function by manipulating an individual patient's microbiota composition and function. We believe that identifying more precise therapeutic targets and developing appropriate rapid diagnostic tools will guide more effective and safer microbe-based induction and maintenance treatments for IBD patients that can be applied in a personalized manner.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.